SciHub
文献互助
期刊查询
一搜即达
科研导航
即时热点
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!
风趣觅荷
Lv3
396 积分
2025-01-13 加入
最近求助
最近应助
互助留言
Design and Implementation of Intelligent Voice Classification Trash Cans
12天前
已完结
Recent Progress in Wearable Microneedle Sensor Devices for Continuous Screening of Interstitial Fluid: A Journey Toward Lab Under the Skin
1个月前
已完结
Recent Progress in Wearable Microneedle Sensor Devices for Continuous Screening of Interstitial Fluid: A Journey Toward Lab Under the Skin
1个月前
已关闭
Recent Progress in Wearable Microneedle Sensor Devices for Continuous Screening of Interstitial Fluid: A Journey Toward Lab Under the Skin
1个月前
已关闭
Surgical margins in head and neck cancer: A contemporary review
1个月前
已完结
FDA approves TROP2-targeted antibody–drug conjugate for breast cancer
1个月前
已关闭
Minimal residual disease as a target for liquid biopsy in patients with solid tumours
3个月前
已完结
Microenvironment‐Regulated Dual‐Layer Microneedle Patch for Promoting Periodontal Soft and Hard Tissue Regeneration in Diabetic Periodontitis
3个月前
已完结
Emerging Combination of Hydrogel and Electrochemical Biosensors
3个月前
已完结
没有进行任何应助
感谢
1个月前
标题错误
1个月前
老师不是这个呀,我求的里面有下面这句话,在您给的PDF里没有搜到 The FDA in January approved Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan (Datroway) for unresectable or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer following endocrine-based therapy and chemotherapy. It is the second TROP2-targeted antibody–drug conjugate (ADC) to market in the US, following Gilead/Immunomedics’ sacituzumab govitecan (Trodelvy).
1个月前
速度真快,帮大忙了,么么哒
3个月前
速度真快,帮大忙了,感谢
3个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论